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ABSTRACT
Bisphosphonate use has expanded beyond traditional applications to include treatment of a variety of low-bone-mass conditions.
Complications associated with long-term bisphosphonate treatment have been noted, generating a critical need for information
describing the local bisphosphonate-cell interactions responsible for these observations. This study demonstrates that a fluorescent
bisphosphonate analogue, far-red fluorescent pamidronate (FRFP), is an accurate biomarker of bisphosphonate deposition and retention
in vivo and can be used to monitor site-specific local drug concentration. In vitro, FRFP is competitively inhibited from the surface of
homogenized rat cortical bone by traditional bisphosphonates. In vivo, FRFP delivery to the skeleton is rapid, with fluorescence linearly
correlated with bone surface area. Limb fluorescence increases linearly with injected dose of FRFP; injected FRFP does not interfere with
binding of standard bisphosphonates at the doses used in this study. Long-term FRFP retention studies demonstrated that FRFP
fluorescence decreases in conditions of normal bone turnover, whereas fluorescence was retained in conditions of reduced bone
turnover, demonstrating preservation of local FRFP concentration. In the mandible, FRFP localized to the alveolar bone and bone
surrounding the periodontal ligament andmolar roots, consistent with findings of osteonecrosis of the jaw. These findings support a role
for FRFP as an effective in vivo marker for bisphosphonate site-specific deposition, turnover, and long-term retention in the skeleton.
 2010 American Society for Bone and Mineral Research.
KEY WORDS: BISPHOSPHONATES; MOLECULAR IMAGING; FLUORESCENCE; OSTEOGENESIS IMPERFECTA; OSTEONECROSIS OF THE JAWIntroduction
Bisphosphonates are a class of drugs used traditionally to treatadult diseases of high bone turnover, such as osteoporosis,
Paget disease, myeloma, and metastatic bone disease.(1)
Bisphosphonates bind directly to mineralized bone surfaces,
where they are taken up by osteoclasts and inactivate osteoclast
activity. The resulting reduction in bone resorption leads to a net
positive bone balance.(2) Recently, the use of bisphosphonates
has been expanding in children and adolescents to treat a variety
of pediatric osteopenic conditions, including fibrous dysplasia,
traumatic osteonecrosis of the femoral head, disuse osteopenia,
and osteogenesis imperfecta (OI).(3–6)
Despite a history of use in adult and pediatric populations,
recent complications have led to calls urging caution for long-
term bisphosphonate use. Low-energy fractures have been
reported in osteoporotic patients treated with bisphosphonates,Received in original form October 15, 2009; revised form January 6, 2010; accepte
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1748possibly resulting from reduced remodeling of microdamage in
bone(7) or from altered material properties.(8,9) OI patients
treated with bisphosphonates have shown delayed healing of
osteotomy sites,(10) delayed tooth eruption,(11) and a remarkable
osteosclerotic phenotype in metaphyseal bone reflecting
treatment during a growth period.(12–15) In a mouse model for
OI, bisphosphonate treatment improves bone size, but bending
strength fails to increase to proportional levels, and bones
remain brittle.(16) In patients treated with high bisphosphonate
doses during cancer treatment, osteonecrosis of the jaw (ONJ)
has emerged as a serious complication, with exposed bone in the
maxillofacial region that persists for at least 8 weeks.(17–21)
Together these findings suggest a critical need for information
describing local drug-cell interactions within the skeleton.
Developing biomarkers for bisphosphonate deposition
and retention would be valuable to understand these
findings.(18)d February 3, 2010. Published online February 8, 2010.
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Bisphosphonates tagged with radionucleotides have been used
as short-term markers of bisphosphonate deposition and
localization in the skeleton. However, a short half-life prevents
these drugs from being useful for long-term studies of retention
posttreatment. Long-term retention of bisphosphonates within
the skeleton has been observed by urinary excretion markers for
up to 8 years after cessation of treatment in youths with severe
osteoporosis.(22) While this method of observation demonstrates
long-term retention, it fails to provide site-specific information on
local drug concentration. Site-specific binding of bisphosphonates
to metabolically active areas in the growing skeleton has been
inferred by the correlation of osteosclerotic lines with the number
and frequency of bisphosphonate treatment cycles in growing
patients.(23) However, direct verification of this association has yet
to be proven. Furthermore, if bisphosphonates retain their
antiresorptive capacity over extended periods of time in the
skeleton, direct visualization of areas that retain high bispho-
sphonate concentrations will be important to understanding their
effect on subsequent healing of damaged tissue.
Recently, the functionalization of the bisphosphonate pami-
dronate with a near-infrared fluorophore has been developed
and characterized.(24,25) This far-red fluorescent pamidronate
(FRFP) has been used as a tool for monitoring bone turnover and
repair(24–26) and extraskeletal calcification in vivo.(25,27–29) Similar
fluorescent bisphosphonate probes have been used to monitor
bisphosphonate-osteoclast interactions in vitro.(30) Using a near-
infrared imaging strategy allows for deep signal penetration
through tissues in a region of the spectrum where tissue
autofluorescence is low, providing high signal-to-noise values.(31)
Despite demonstration of this imaging strategy in a variety of
disease contexts, the potential of FRFP as a tracer compound for
bisphosphonate delivery and retention in vivo has yet to be
established. Use of FRFP as an in vivo bisphosphonate marker
would provide a noninvasive, repeatable methodology capable
of directly visualizing the deposition and long-term retention or
release of bisphosphonate from the skeleton. This study
validates a fluorescent bisphosphonate analogue as a biomarker
for bisphosphonate deposition and retention in vivo to monitor
local drug concentration in a site-specific manner.
Materials and Methods
In vivo imaging probes
FRFP680 and FRFP750 (Osteosense, VisEn Medical, Bedford, MA,
USA) have nonoverlapping excitation (680 and 750 nm) and
emission (700 and 780 nm) peaks to allow for multichannel
imaging. Probes consist of a pamidronate backbone functiona-
lized with near-infrared fluorophore off the amino terminus of
the R2 side chain. IRDye 800CW carboxylate (LI-COR Biosciences,
Lincoln NB. USA) is a nonreactive control probe with similar
spectral properties to FRFP750. Unless otherwise noted, standard
animal doses of each probe are prepared as 100 nmol/kg in
150mL of PBS and administered by i.v. tail vein injection.
In vitro binding assays
To create bone powder for in vitro binding assays, several rat
forelimbs and hindlimbs were dissected free from soft tissue andFLUORESCENT BISPHOSPHONATE IMAGING IN BONEcut at the proximal and distal ends, and bone marrow was
flushed with distilled water. To defat the bones, specimens were
placed in a solution of 1:1 chloroform-methanol for 4 hours and
then removed and sonicated in distilled water. Bones were dried,
placed in 100% ethanol for 1 hour, and then placed in ethyl ether
for 30minutes. Specimens were dried overnight at 37 8C. Once
dry, defatted bone samples were homogenized, producing
particles varying from 42 to 295mm in diameter. Powder was
suspended in 0.2M Tris-formate solution (pH 7.2) and kept at
4 8C.
In vitro dose response
Suspensions of approximately 1.25mg/mL of bone powder were
combinedwith varying concentrations of FRFP750 (0 to 6mM) for
1 hour at room temperature in a Millipore 96-well filter plate
(Bedford, MA, USA). To separate unbound FRFP from FRFP bound
to bone particles in solution, plates were centrifuged at 1000 g
for 10minutes. Eluted, unbound FRFP was collected, and
postincubation fluorescence was assessed by plate reader assay
(SpectraMax M5, Molecular Devices, Sunnydale, CA, USA).
Postincubation fluorescence was compared with preincubation
fluorescence to determine the total amount of FRFP bound to
bone powder in vitro in relation to a calibrated curve of known
FRFP concentrations.
In vitro competitive inhibition
In order for FRFP to be used as a tracer compound for
bisphosphonates, it should compete for the same mineral
binding sites as unlabeled drug. Competitive inhibition assays
were performed comparing FRFP binding in the presence of
unlabeled pamidronate (PAM) or alendronate (ALN). As before,
50-mL suspensions of bone powder were mixed with FRFP
(1.33mM) and increasing concentrations of PAM or ALN (0 to
3350mM; Sigma-Aldrich, St. Louis, MO, USA) for 1 hour at room
temperature in a total volume of 100mL. As before, unbound
FRFP was separated, and FRFP bound to bone particles was
assessed by comparing pre- and postincubation fluorescence
with a calibrated curve of known FRFP concentrations.
In vivo FRFP dose response
To demonstrate the linearity of the in vivo bone fluorescence
response to FRFP dose, 7- to 8-week-old male Balb/c mice were
administered a range of FRFP (12.5 to 150 nmol/kg, n¼ 3 to 4 per
group) by tail vein injection in total volumes of 150mL, and
baseline tissue autofluorescence was compared with that in
uninjected controls (n¼ 2). Twenty-four hours after injection,
mice were euthanized, and femurs were dissected and imaged
by fluorescence reflectance imaging (Maestro Imaging System,
Cambridge Research and Instrumentation, Woburn, MA, USA)
using 710- to 760-nm bandpass excitation and 810-nm emission
at constant exposure. Mean distal femoral fluorescence was
assessed within 0.03-cm2 regions of the bone.
In vivo competitive inhibition
For FRFP to function quantitatively in vivo in the context of a
bisphosphonate treatment regime, the treatment dose ofJournal of Bone and Mineral Research 1749
bisphosphonate should not interfere with FRFP binding. To
determine whether a surplus of bisphosphonate binding sites
exists at relevant skeletal locations, 7- to 8-week-old male Balb/c
mice (n¼ 3 per group) were injected with a cocktail of FRFP and
increasing concentrations of nonlabeled PAM up to 500 the
FRFP concentration. Then 24 hours after injection, mice were
euthanized, and femur, tibia, and mandible were dissected into
ice-cold Hank’s buffered salt solution and kept dark until ex vivo
imaging. Ex vivo imaging was performed as done previously,
with exposure set to maximize fluorescence per anatomic
location while avoiding detector saturation.
To assess fluorescence, distal femoral signal was quantified by
measuring a 0.03-cm2 region of interest centered over the distal
femoral growth plate. The proximal tibial signal was assessed by
tracing the proximal tibial growth plate from an anterolateral
view to measure average fluorescence. In the mandible, a lateral
view was assessed for total mandible fluorescence above
background. All fluorescence was assessed using ImageJ
(National Institutes of Health, Bethesda, MD, USA).
In vivo time course
To determine delivery rate and factors associated with FRFP
binding, FRFP750 was administered to the Brtl/þ mouse, a
knock-in model for OI whose type I collagen carries a COL1A1
Gly349Cys substitution from the mutant allele.(32,33) In this
experiment, FRFP was used to assess differences in bispho-
sphonate delivery between male Brtl/þ and wild-type mice at 2
and 6 months of age (n¼ 6 to 9 per group). Brtl/þ mice used in
these experiments were offspring from Brtl/Brtlwild-type
matings. Following FRFP injection, proximal tibias were shaven
and depilated (Nair), and proximal tibial fluorescence was
monitored by in vivo noninvasive serial imaging at 2, 6, and
24 hours after injection (Maestro, CRi). An additional group of 6-
month-old Brtl/þ males (n¼ 6) was injected with a comparable
dose of the control dye, IRDye 800CW carboxylate (LI-COR
Biosciences) and imaged in vivo (Pearl Imager, LI-COR
Biosciences) to demonstrate binding specificity of FRFP and
washout of the nonbisphosphonate control fluorophore.
At 24 hours, mice were euthanized, and femur, tibia and
mandible were dissected and imaged for FRFP delivery. Ex vivo
bone fluorescence was assessed as described earlier. Following
fluorescent imaging, femurs were imaged by micro–computed
tomography (mCT; GE eXplore Locus SP, GE Healthcare, London,
Ontario, Canada) and reconstructed at 18-mm voxel size to
correlate bone fluorescence with bone surface area in the
distal femur. Trabecular bone regions of the distal femur 1.5 to
1.8mm in length were isolated independent of cortical bone
at the growth plate. Bone surface area was assessed using
manufacturer-provided software (MicroView ABA 2.2, GE
Healthcare).
Long-term FRFP retention
To investigate the ability of FRFP to be used as a long-term
marker of bisphosphonate retention, we used 8-week-old male
Brtl/þ mice. The mice were divided into untreated and treated
groups (n¼ 3 per group). Untreated mice received two rounds of
FRFP injection at 8 (FRFP750) and 9 (FRFP680) weeks of age.1750 Journal of Bone and Mineral ResearchTreated mice received identical doses of FRFP but were
coinjected with high-dose PAM (7.5mg/kg) to inhibit bone
turnover and prevent removal of FRFP from the bone matrix. At
10 weeks of age, the mice were euthanized, and their limbs were
dissected for imaging. To determine percent retention of
FRFP750 after 2 weeks in vivo and FRFP680 after 1 week in
vivo, two control groups receiving FRFP750 at 8 weeks of age and
FRFP680 at 9 weeks of age were euthanized 24 hours after probe
injection and analyzed in the same manner as the experimental
groups. Treated and untreated bone fluorescence was compared
with 8- and 9-week-delivery control values to determine percent
of 24-hour dose retained under conditions of normal or
downregulated bone turnover.
Histologic analysis
To visualize local FRFP delivery in the mandible, 1 FRFP
mandibles were dehydrated, embedded undecalcified in
polymethylmethacrylate (PMMA), thick sectioned in a frontal
plane using a diamond band saw, and ground to a final section
thickness of 50 to 100mm. Sections were imaged using
epifluorescence with a custom near-infrared filter set (excitation
735/50 nm; emission 790/40 nm) on a Zeiss Axiovert system
equipped with an iXONþ EMCCD camera (Andor Technology,
South Windsor, CT, USA). To visualize FRFP delivery in the femur
and tibia, limbs were snap frozen in optimal cutting temperature
compound (OCT; Tissue-Tek, Torrance, CA, USA) following
dissection, and cryosectioned at 4 to 7mm (CryoJane Tape
Transfer System, Instrumedics, Richmond, IL, USA). Sections were
imaged under confocal microscopy (Zeiss LSM 510-META; Carl
Zeiss MicroImaging Inc., Thornwood, NY, USA) equipped with a
Helium-Neon 2 laser for excitation (633 nm). Following confocal
imaging, sections were stained with hematoxylin and eosin and
imaged under brightfield microscopy. Confocal and bright-field
images were aligned to demonstrate FRFP location.
All animals in this study were maintained and processed in
accordance with the NIH Guide for the Care and Use of Laboratory
Animals.
Statistics
Differences in fluorescence between groups in in vivo
competitive inhibition data were assessed by one-way ANOVA.
Differences in fluorescence attributed to genotype, treatment, or
time in delivery and retention assays were assessed by two-way
ANOVA followed by Bonferroni post hoc tests. Statistical
significance was assessed at p< .05. All data presented as
mean SD.Results
In vitro binding assays
FRFP binds to bone particles in solution dose-dependently, with
binding saturating at high concentrations (Fig. 1A). Scatchard
analysis (inset) suggests that the maximum FRFP binding in vitro
is 2.25mmol/g of mineral. ALN and PAM were both effective atKOZLOFF ET AL.
Fig. 1. (A) FRFP binds to bone powder dose-dependently and saturates at high doses. (B) PAM and ALN both compete FRFP (1.33mM) away from bone
particle suspension.competing FRFP away from bone powder in an in vitro
competitive inhibition assay (Fig. 1B).
In vivo FRFP dose response
To demonstrate linear uptake of FRFP in vivo, mice were injected
with varying doses of FRFP to monitor linearity of bone
fluorescence. Mean fluorescence of the distal femur is linear from
approximately 1/8 to 1½ times the imaging dose of 100 nmol/kg
(Fig. 2), suggesting a linear reporting of bone fluorescence based
on local drug delivery.
In vivo competitive inhibition and localization
In order for FRFP to function effectively as a tracer in vivo in the
context of a bisphosphonate treatment regime, the treatment
dose of bisphosphonate should not interfere with FRFP binding.
In vivo competitive inhibition shows that local delivery of FRFP to
the femur, mandible, and tibia is not affected by increasing doses
of therapeutic bisphosphonates for concentrations up to 500
FRFP (Fig. 3, one-way ANOVA, no significance detected). In
contrast to in vitro competitive inhibition results, where mineral-
binding sites are limited by the amount of powder in solution,Fig. 2. (A) Femoral region of interest chosen for dose-response measures of FRF
FLUORESCENT BISPHOSPHONATE IMAGING IN BONEthese data suggest that in vivo, bisphosphonate binding occurs
without saturation of mineral-binding sites at the concentrations
examined.
FRFP localizes to regions typically associated with high bone
turnover, such as the distal femoral growth plate, the femoral
head, and the proximal tibial growth plate. In the femur, FRFP is
found in bone surrounding the growth plate, in both the
metaphysis and epiphysis (Fig. 3A). In the mandible, FRFP
localizes to the temporomandibular joint and is highly bound in
the alveolar bone adjacent to the molars (Fig. 3B). Histologic
sectioning of the mandible of injected mice reveals widespread
FRFP localization (Fig. 4), including the molar, alveolar bone,
and incisor root, whereas sections from uninjected animals did
not show significant tissue autofluorescence (data not shown).
FRFP binding (pseudocolored red) is observed in regions
typically affected by ONJ, such as the alveolar bone adjacent
to the periodontal ligament (Fig. 4B, D, E) andmolar root (Fig. 4C).
Additional binding is also seen throughout the tooth itself,
including the dentin-enamel junction of the incisor (Fig. 4F),
within themolar dentin space (Fig. 4G,10), and in what appears
to be channels feeding the molar (Fig. 4H). This binding may
represent vascular sinusoids deficient in endothelial lining cells
or a relatively permeable cell junction connection that allowsP delivery. (B) Bone fluorescence is linear with administered dose of FRFP.
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Fig. 3. Competitive inhbition of FRFP with PAM was not found to occur in vivo in the (A) femur, (B) mandible, or (C) tibia, demonstrating no interference
between FRFP binding and therapeutic bisphosphonate dosing.FRFP to penetrate the cell layer and label the mineralized surface
surrounding the vasculature.
In vivo time course
Proximal tibial fluorescence was monitored in Brtl/þ and wild-
type mice at 2, 6, and 24 hours after a single FRFP injection.
Consistent with previous studies showing rapid binding of
pamidronate to bone,(34) FRFP localizes to the proximal tibia
rapidly, with approximately 90% of 24-hour fluorescence
occurring within 2 hours of injection (Fig. 5B). In contrast,
nonbisphosphonate carboxylate control dye clears from the
system rapidly, with tibial fluorescence at background levels
24 hours after injection (data not shown).
Tibial fluorescence was marginally but not significantly
reduced in 6-month-old Brtl/þ mice at all time points studied.
Ex vivo distal femoral fluorescence demonstrated that this
marginal decrease in femoral fluorescence corresponds to an1752 Journal of Bone and Mineral Researchosteopenic phenotype reflected by mCT analysis (Fig. 5C).
Plotting femoral fluorescence versus distal femoral bone surface
area across age and genotype highlights the dependency of
FRFP binding on bone surface area in these animals (Fig. 5D).
Long-term FRFP retention
FRFP injected into 8-week-old Brtl/þ mice in conjunction with
high-dose PAM is significantly retained in bone over 1 and
2 weeks compared with untreated animals (Fig. 6). PAM-treated
femurs demonstrate over 100% of the 24-hour control signal,
suggesting continued drug delivery after the 24-hour time point,
whereas mandibular retention is less than 100% in treated
groups, suggesting an altered delivery and retention between
groups. Untreated mandibles appear to retain a greater
proportion of FRFP than femurs, suggesting a greater retention
of bisphosphonate within the mandible. Dual labeling is
apparent in both femurs and mandibles, whereas interlabelKOZLOFF ET AL.
Fig. 4. In situ fluorescence of FRFP signal (red) in the mandible demonstrates widespread bisphosphonate localization in regions of concern for ONJ.
(A) 2.5 overview highlighting location of subsequent 10 (G) and 20 panels (B–F, H). (Inset) Whole-mandible fluorescence and location of frontal
section. (B) Alveolar bone adjacent to periodontal ligament. (C) Base of molar root. (D) Alveolar bone. (E) Bone surrounding incisor periodontal ligament
space. (F) Incisor dentin-enamel junction. (G)10 magnification of molar dentin space. (H)20 magnification of panel G showingmolar dentin space and
supplying vasculature. (I) Fluorescence FRFP signal in the proximal femur shows FRFP binding in the epiphyseal (e) and metaphyseal (m) regions. Growth
plate (gp) is shown for reference. Scale bar¼ 50mm.distance appears significantly reduced in PAM-treated animals
(Fig. 6).
Discussion
After 40 years of development and treatment experience,(35)
bisphosphonate usage is expanding beyond traditional low-
bone-mass or high-bone-turnover applications to include
treatment of pediatric low bone mass(3–6) and is being proposed
for use in treating osteonecrosis of the femoral head,(36)
stabilization of implant fixation,(37) and the treatment of
rheumatoid arthritis.(38) However, several complications have
been identified as associated with bisphosphonate treatment,
leading, in some cases, to necrosis or unexplained bone
failure.(7,19–21) Emerging evidence suggests that bisphospho-
nates may affect osteoblasts and osteocytes directly, with some
studies showing intereference with apoptosis, resulting in
prolonged bone formation,(39,40) whereas other studies suggest
bisphosphonate toxicity on osteoblasts.(16,41,42) Additionally, the
interaction between bisphosphonates and nonbone cells, such
as T cells, has been described.(43) Therefore, the development of
sensitive techniques to assess local bisphosphonate concentra-
tion at relevant skeletal sites would advance understanding of
the interplay between bisphosphonates and bone cells in vivo.
The data presented here demonstrate that a far-red fluorescent
bisphosphonate tracer can be the basis of an imaging strategy
for assessing bisphosphonate delivery and retention in vivo.
Delivery of FRFP to the skeleton is rapid, and binding to
mineral substrates is consistent with nonlabeled bisphosphonate
binding. In vitro, alendronate and pamidronate were comparable
in displacing FRFP, consistent with similar binding constants
found between these drugs in (14)C-labeled bisphosphonate
studies.(44) In vivo, nearly 90% of the fluorescent signal from FRFP
localized to bone within 2 to 6 hours of injection. This comparesFLUORESCENT BISPHOSPHONATE IMAGING IN BONEfavorably with studies of (14)C-labeled pamidronate, in which
skeletal distribution is rapid initially, slows after 6 hours, and
yields peak binding after 24 hours.(34)
Bisphosphonate-mineral binding traditionally has been attrib-
uted to the hydroxyl group at the R1 position off the central P-C-P
backbone.(45–48) However, recent evidence points to a role of
the R2 side chain in governing binding as well.
(49) In this study,
Scatchard plot analysis suggests a maximum binding of
2.25mmol FRFP per gram of mineral in vitro. Although there is
no comparison data for pamidronate binding capacity in the
literature, reported alendronate binding capacity is an order of
magnitude higher. Sato and colleagues reported alendronate in
vitro binding capacity of 100mmol/g,(50) whereas data extra-
polated from Leu and colleagues suggest a binding capacity
closer to 10 to 20mmol/g.(44) Alendronate contains only one
additional methyl group on the R2 side chain compared with
pamidronate, and it has a Ki constant similar to that of
pamidronate,(44) allowing this comparison to be made. FRFP
contains a fluorophore functionalized to the R2 side chain of
pamidronate, which may sterically limit the total amount of FRFP
capable of binding to the bone surface and reduce the mineral-
binding capacity below that of alendronate.
Our in vivo binding data suggest that FRFP fluorescence
depends on the quantity of bone available. More specifically,
since FRFP binding appears to be a mineral surface-dependent
process,(24) a high linear correlation was observed between distal
femoral fluorescence and bone surface area. Injections of up to
14mg/kg of nonlabeled pamidronate in vivo were unable to
compete with FRFP from the bone surface at the concentrations
used for imaging. Pamidronate accumulation in the skeleton is
linear through at least 30mg/kg doses,(34) and in vivo bispho-
sphonate binding-site saturation is suggested to be ‘‘practically
impossible’’ in doses used to treat osteoporosis.(51,52) While in
vitro competitive inhibition experiments in this study were
performed with both pamidronate and alendronate, we onlyJournal of Bone and Mineral Research 1753
Fig. 5. (A) Proximal tibia of Brtl/þ and wild-type mice as monitored by in vivo serial imaging over 24 hours. FRFP fluorescent signal is shown (FRFP) with
corresponding white-light reference image (WL). (B) Delivery of FRFP is rapid, with nearly 90% of 24-hour dose delivered within 2 hours. Six-month-old
Brtl/þ tibias demonstrate reduced fluorescence versus wild-type and 2-month-old Brtl/þ animals. (C) Ex vivo imaging of femurs from 2- and 6-month-old
Brtl/þ and wild-type mice demonstrates a reduction in distal femoral fluorescence that corresponds to osteopenia noted in mCT cross sections. (D) Distal
femoral fluorescence is linearly correlated with total distal femoral bone surface area, suggesting that FRFP, like bisphosphonates, binds in a bone surface–
mediated manner.performed in vivo competitive inhibition with pamidronate.
However, similar findings could be inferred based on results
suggesting that saturation of alendronate in the skeleton occurs
only at high doses, when single i.v. injections exceed 10mg/
kg.(53) Therefore, because tracer doses of FRFP at the con-
centrations used in this study are small compared with such
saturation doses, our data suggest that FRFP can be used in
conjunction with bisphosphonate treatment in vivo without
interfering with FRFP signal at the low concentration used here.
In this study, aged Brtl mice with low bone mass in the distal
femur showed correspondingly low FRFP delivery to those
regions, corroborating the dependence of bisphosphonate
delivery, at least in part, on the number of mineralized surfaces
available for drug binding. In a clinical study of pamidronate
treatment in children with types III and IV OI, significant
variability existed in the individual response of patients to
treatment.(54) Our current data suggests that existing bone mass
may play an important role in determining local concentration
and thus possibly effectiveness of antiresorptives in vivo. This1754 Journal of Bone and Mineral Researchcontrasts with evidence suggesting that among postmenopausal
women treated with once-weekly bisphosphonates, nonrespon-
ders to the drug were likely to have a higher baseline
trochanteric bone mineral density.(55) Therefore, factors in
addition to bone mass, including local vascular delivery and
local bone turnover rates, likely play a role in determining the
effectiveness of bisphosphonate treatment for low bone mass.
Animals labeled with FRFP for 1 and 2 weeks demonstrate
fluorescence retention that correlates with local bone turnover
conditions. In animals cotreated with therapeutic doses of
pamidronate, fluorescence signal is preserved throughout the 2
weeks, whereas fluorescence decreases significantly in untreated
animals. The prolonged retention and fluorescence of local FRFP
in a low-bone-turnover condition suggests that changes in FRFP
signal may be used as a surrogate marker for turnover of labeled
bone in the presence or absence of treatment doses of
bisphosphonate.
At 6 months, Brtl mice had a reduced bone-formation rate
compared with wild-type mice, which also may contribute toKOZLOFF ET AL.
Fig. 6. FRFP retention in untreated and PAM-treated animals after 1 (red) and 2 (green) weeks in vivo in femur (A) and mandible (B). (C, D) Percent signal
retention derived by normalizing 1- and 2-week signal by specimens assayed 24 hours after FRFP delivery.reduced bisphosphonate delivery.(56) Conversely, high levels of
bone turnover may play a role in clearing the skeleton of
deposited bisphosphonate. Pamidronate has been detected in
the urine of OI patients 8 years following cessation of
treatment,(22) suggesting that despite local bisphosphonate
concentration, drug still can be turned over in the body as
osteoclasts attempt to remodel treated bone. Using FRFP as a
tracer compound for bisphosphonate retention will allow for
long-term analysis of site-specific turnover of drug in vivo.
Additionally, turnover is often inversely correlated with mineral
crystal size. As crystalline size decreases, the specific surface area
will increase, potentially allowing for greater bisphosphonate
binding within a given region of bone. While not investigated in
this study, FRFP fluorescence may provide insight into local
mineral crystal size based on available bisphosphonate binding
sites. Crystal size is governed by many factors, including age,
collagen and noncollagenous template, diet, and disease,(57) and
crystalline size and purity may be associated with fracture risk
independent of differences in bone mass.(58,59) Therefore,
understanding whether local bisphosphonate concentration is
governed by mineral crystal size may be important in under-
standing treatment for other bone disorders.
Together these data suggest that FRFP imaging is a viable
technique to monitor the delivery and retention of bispho-
sphonates in vivo. This study was performed using a fluorescent
pamidronate analogue. While different bisphosphonates have
different binding affinities and interactions with hydroxyapa-
tite,(49) to date, we are unaware of studies that demonstrate
heterogeneous site-specific binding of different bisphospho-
nates to different anatomic locations. Given this, FRFP can be
used to monitor factors such vascular delivery and available
binding surfaces independent of bisphosphonate type. Other
fluorescent bisphosphonate analogues have been described(30)FLUORESCENT BISPHOSPHONATE IMAGING IN BONEbut have not yet been tested against FRFP to determine whether
heterogeneous site-specific binding of different bisphospho-
nates occurs.
This technique will be useful for examining side effects that
have been associated with bisphosphonate treatment. Bispho-
sphonates have been used to treat low bone mass found in
osteogenesis imperfecta for over 15 years.(60) Intravenous
bisphosphonate therapy produces positive gains in vertebral
morphology and bone mineral density in children with
osteogenesis imperfecta.(54,61–63) However, in controlled studies
of bisphosphonate treatment in osteogenesis imperfecta, no
difference has been found in nonvertebral fracture rates in
patients given oral alendronate, intravenous neridronate, or
pamidronate.(64) This site specificity of effectiveness may relate
to site-specific differences in bisphosphonate delivery or
retention in vivo. This study demonstrates heterogeneous
bisphosphonate distribution among skeletal locations, suggest-
ing that regions of highest bone turnover may experience the
highest rate of drug delivery but also may be susceptible to high
rates of drug removal depending on applied dose.
The characteristic radiographic feature of bisphosphonate
treatment in a growing skeleton is the metaphyseal banding
patterns originating at the growth plate and extending through
the metaphysis into the diaphysis as the patient grows.(6,12–14,23)
The intensity, timing, and spacing of these lines correlate with
the dose and frequency of bisphosphonate delivery and suggest
regions of unresorbed bone and/or calcified cartilage resulting
from altered growth plate remodeling.(23) A similar pattern of
deposition and spacing of FRFP during treatment suggests that
these sclerotic areas contain high local bisphosphonate
concentration. The long-term functional implication of this
finding is unclear. While these sclerotic lines add material to an
osteopenic bone, the orientation of these bands may not beJournal of Bone and Mineral Research 1755
consistent with the primary loading direction of the bone. It is
also possible that these regions may act as stress risers, and a
case report has described fractures at one such site when
treatment was halted prior to fusion of the growth plate.(15) The
combination of high stress plus high concentration of
antiresorptive drug may make these locations prone to
accumulated fatigue damage incapable of normal tissue repair
over time. Bisphosphonate treatment has been shown to delay
tooth eruption in treated OI children, presumably by interfering
with osteoclast-mediated bone remodeling or tooth root
development.(11) While this study did not focus specifically on
tooth development, we noted significant FRFP localization
within both mandibular bone and tooth structures. FRFP was
found in the vascular channels supplying the molars, within the
molar dentin space, and at the dentin-enamel junction of the
incisor. Additionally, FRFP localized in the alveolar bone adjacent
to the periodontal ligaments and molar roots. These are regions
of bone that may be associated with the thickened alveolar bone
and regions of necrotic bodies that have been found in the
mandible in patients with osteonecrosis of the jaw.(65) High levels
of an antiresorptive in the oral cavity may induce low bone
turnover, resulting in decreased blood flow, bone cell necrosis,
and cellular apoptosis, mechanisms that have been proposed to
be responsible for the nonhealing lesions typical of ONJ.(20) This
imaging strategy may be useful to pursue these hypotheses by
directly visualizing bisphosphonate delivery and retention in
relevant skeletal sites.
The usefulness of FRFP as a biomarker for bisphosphonate
delivery and retention in vivo is bolstered by parallel studies
between FRFP and radiolabeled bisphosphonates. FRFP has been
used to visualize osteogenic labeling in bone-defect models,
with high fluorescence concentrating in areas of high osteo-
blastic activity.(24,26) These studies corroborate earlier studies
using radiolabeled bisphosphonates to demonstrate high drug
delivery to sites of active bone regeneration during fracture
repair(66) and histologic studies demonstrating unremodeled
cartilage retained in fracture callus treated with bisphospho-
nate.(67) Similarly, FRFP, when injected into mice with osteolytic
lesions resulting from tumor xenograft injections, localizes under
osteoclasts at the tumor-bone interface.(24) Bisphosphonates
have long been described as localizing underneath osteoclasts,
and fluorescent bisphosphonate strategies have been used to
visualize osteoclastic uptake of drug during bone resorption.(30)
Near-infrared contrast agents are less attenuated by overlying
tissue than similar green-shifted probes.(31) However, while near-
infrared signals can propagate between 5 and 12 cm through
soft tissues,(68) using the fluorescence reflectance imaging
described in this study, signals are still surface-weighted(69)
and may be limited to penetration depths of less than 1 cm.(70)
Therefore, when performing any type of fluorescence imaging,
choice of anatomic location is critical. In this study, we imaged in
vivo proximal tibial FRFP signal owing to ease of imaging at this
anatomic location and relatively low tissue coverage. However,
we also imaged ex vivo distal femoral FRFP signal from the same
animals, and signals from these two locations were highly
linearly correlated (r2¼ 0.63, p< .0001). Femoral, mandibular,
and tibial specimens all were imaged ex vivo to allow better
visualization of signal without overlying tissue. Advances in1756 Journal of Bone and Mineral Researchoptical imaging technology continue to improve on quantitative
fluorescence imaging. Fluorescence molecular tomography
(FMT) is less dependent on depth of signal than fluorescence
reflectance imaging(69,70) and has been used to visualize and
quantify FRFP and similar near-infrared probes in vivo within the
skeleton.(26,71) Further advances will continue to widen options
for using agents such as FRFP for in vivo imaging of biologic
activity.
In conclusion, fluorescent bisphosphonate imaging is a valid
technique for visualizing site-specific bisphosphonate delivery
and retention in vivo. Small tracer doses are delivered rapidly in
the skeleton and can be used in the context of a standard
bisphosphonate treatment regime without interfering with drug
binding. FRFP binding relies on local bone surface area, and
removal of tracer probe is reflected in animals undergoing
increased bone turnover. Combining fluorescent bisphospho-
nates with other fluorescent markers of osteoblastic,(72)
osteocytic,(73) or osteoclastic(71) markers will facilitate in vivo
and histologic imaging studies to investigate models of
osteoporosis, osteogenesis imperfecta, and osteonecrosis of
the jaw, where drug-cell interactions leading to a positive or
negative outcome have yet to be described.
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